A Form 4 filed with the SEC on August 13, 2026, discloses that Andrew Cheng, a director of Damora Therapeutics, Inc. (NASDAQ:DMRA), was granted a stock option to purchase 30,350 ordinary shares on August 12, 2026.

Key Highlights

  • Reporting person: Andrew Cheng, identified as a Director of Damora Therapeutics, Inc.
  • Transaction date: August 12, 2026, with the filing submitted on August 13, 2026.
  • Option grant: A stock option (right to buy) covering 30,350 ordinary shares was acquired, with a transaction code of A (acquired).
  • Exercise price: $31 per share, with an expiration date of August 12, 2036.
  • Price of derivative security: $0, as reported in the filing.
  • Vesting schedule: The option vests in equal monthly installments through August 12, 2029, subject to continued service.
  • Resulting ownership: 30,350 derivative securities beneficially owned following the transaction, held directly.

Stock Option Award Details for Andrew Cheng at Damora Therapeutics

According to the filing, Andrew Cheng, a director at Damora Therapeutics, Inc. (NASDAQ:DMRA), received a stock option grant on August 12, 2026. The option represents the right to purchase 30,350 ordinary shares of the issuer's common stock at an exercise price of $31 per share. The option is classified as a derivative security acquired (transaction code A) and was reported at a price of $0.

The filing notes, in the explanation of responses, that "this option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date." The option carries an expiration date of August 12, 2036. Following this transaction, the filing reports that Cheng directly beneficially owns 30,350 derivative securities. No non-derivative securities transactions were reported in Table I of the filing.

The Form 4 was filed by one reporting person and was signed by Garrett Winslow on August 13, 2026, on behalf of Andrew Cheng. No amendment date was listed, indicating this is an original filing.

What Was Disclosed

The filing discloses a stock option grant of 30,350 shares to director Andrew Cheng at an exercise price of $31, expiring August 12, 2036, with vesting in equal monthly installments through August 12, 2029, contingent on continued service.